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We report a now 6-year-old African-American male with both Alagille syndrome and pediatric sarcoidosis. With a
prior JAG1 mutation positive diagnosis of Alagille syndrome, he presented to the hospital with a subacute,
predominantly respiratory febrile condition, eventually diagnosed as sarcoidosis. A liver biopsy revealed paucity of
bile ducts and scattered epithelioid granulomas, while a skin biopsy showed granulomatous angiitis, a
manifestation of sarcoidosis not yet reported in a pediatric patient. He has subsequently been treated with
corticosteroids, mycophenolate mofetil, and infliximab with clinical response. Alagille syndrome and sarcoidosis
have not yet been reported in the medical literature in the same patient to the best of our knowledge. We briefly
review these two seemingly unrelated conditions and propose a possible common pathogenic mechanism.
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Sarcoidosis is a systemic granulomatous disease of un-
known etiology that may affect many organ systems.
The lungs are the most commonly involved organs in
adults. Adults with sarcoidosis often have lymphadenop-
athy and systemic manifestations, such as fever and
weight loss. Diagnosis of pediatric sarcoidosis, as in
adults, requires demonstration of non-caseating granu-
lomata in one or more organs in the setting of consistent
clinical or radiographic findings and the exclusion of in-
fectious granulomatous conditions. There is no singular
diagnostic lab test [1]. Derangement in calcium occurs
in 30% of children with sarcoidosis and manifests as
hypercalciuria, with or without hypercalcemia [2].
Hypercalcemia is more prevalent in affected children
than adults. An elevated angiotensin converting enzyme
(ACE) level can be found in sarcoidosis patients, how-
ever it is a less sensitive test in children than in adults
and is thought to be a product of the epithelioid cells of
the sarcoid granuloma [1]. In addition, serum lysozyme
can be used as a marker for sarcoidosis. In one Japanese
study, lysozyme had a sensitivity of 79% for predicting
sarcoidosis. That study found that lysozyme levels* Correspondence: mmannion@peds.uab.edu
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reproduction in any medium, provided the ortended to increase with the number of organ systems
involved and the disease activity [3].
Pediatric sarcoidosis is rare, and its true incidence is
unknown. A recent Danish study estimates the incidence
at 0.22-0.27 per 100,000 children younger than 15 years
of age but, different geographic regions or racial groups
may have a higher prevalence [2]. Most cases of
pediatric sarcoidosis are diagnosed in the pre-adolescent
or adolescent age groups. By contrast, there is an early-
onset form that occurs in children up to age 4 or 5 years
and is usually characterized by boggy arthritis, rash, and
uveitis [4]. Onset frequently occurs in the first year of
life, and the classic presentation is rash (usually papular
and erythematous) or arthritis (usually a boggy teno-
synovitis) without pulmonary involvement, followed by
uveitis. Although pulmonary involvement is not typical
at diagnosis, it can develop later in the disease course.
Blau syndrome is a triad of synovitis, uveitis and rash
with an autosomal dominant inheritance of a mutation in
CARD15 (caspase recruitment domain)/NOD2 (nucleotide
binding oligomerization domain) on chromosome 16 [2,5]
and may represent a substantial subset of what is called
early-onset sarcoidosis. In addition to the familial Blau
syndrome, there have been reports of sporadic mutations
in CARD15 resulting in early onset sarcoidosis [6].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Liver biopsy at nine weeks consistent with Alagille
syndrome. (A) Canalicular cholestasis (arrow) with scattered hepatic
giant cells containing eight to ten nuclei (asterisks), and (B) a
representative portal tract containing two small dilated veins, a small
artery, and no recognizable bile ducts. (A and B, hematoxylin and
eosin, 132x original magnification).
Figure 2 Liver biopsy at 26 months consistent with both
Alagille syndrome and sarcoidosis.(A) Small portal tract with
inconspicuous blood vessels and no recognizable bile ducts, no
cholestasis, and no giant cell transformation in the hepatic
parenchyma, and (B) a granuloma with a central cluster of
epithelioid histiocytes partially surrounded by a band of small
mature lymphocytes. (A and B, hematoxylin and eosin, 132x original
magnification).
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coidosis are often more similar to adults with lung in-
volvement and constitutional symptoms [1,2]. Almost
half of children with sarcoidosis show restrictive lung
disease on pulmonary function testing [2]. If there is
pulmonary involvement, hilar adenopathy is a hallmark
finding on chest radiograph [1,2]. Peripheral lymphaden-
opathy is also a common finding in older children with
sarcoidosis, such that peripheral lymph node enlarge-
ment occurs in 40-70% of children with sarcoidosis [2].
In addition, many children with sarcoidosis have cutane-
ous manifestations, such as erythema nodosum, papules,
plaques, nodules, and changes in pigmentation [1]. Erythema
nodosum can be seen in 31% of children with sarcoidosis
[2]. Many children with sarcoidosis also have ocular in-
volvement. Most commonly, patients have uveitis, but
choroidal or conjunctival granulomata can also be seen
[2]. Other organ systems, including the liver, can also be
involved [1]. While genetic mutations in CARD15/NOD2
can be demonstrated in early onset sarcoidosis and Blau
syndrome, there has not been a definitive genetic muta-
tion associated with adult sarcoidosis or sarcoidosis in
older children, and mutations in CARD15/NOD2 are not
found in these patients [2].
Alagille syndrome is a heritable form of chronic liver
disease in childhood associated with a mutation in JAG1.
Patients with this syndrome have hypoplastic intrahepa-
tic bile ducts with patent extrahepatic bile ducts [7-9]
Other findings of the syndrome can include congenital heart
disease, characteristic facial features, butterfly vertebrae,
growth retardation, renal abnormalities, abnormal eye find-
ings, pancreatic disease, and intracranial hemorrhage [7-9].
The most common form of cardiovascular involvement
in Alagille syndrome is peripheral pulmonary artery
stenosis. Liver biopsy reveals intrahepatic cholestasis in
association with a relative paucity of intrahepatic inter-
lobular bile ducts [7-9]. A prior association of Alagille
syndrome and sarcoidosis has not been previously
reported.
Case presentation
A 2-year-old male with a known history of genetically
confirmed Alagille syndrome presented to the hospital
with tachypnea, respiratory distress, and a fever of 104°F.
He had multiple hospitalizations in the preceding
3 months for similar symptoms and had been diagnosed
with pneumonia 3 times and cholangitis once. He had
recently finished a course of intravenous antibiotics for
presumed pneumonia 2 days prior to presentation.
The patient’s past medical history was significant for
Alagille syndrome which presented as direct hyperbiliru-
binemia at 2 months of age. Liver biopsy was performed
at 3 months and revealed cholestasis, paucity of bile
ducts and giant cell transformation (Figure 1), consistentwith Alagille syndrome. He was also noted by imaging
and clinical examination to have butterfly vertebrae,
right and left pulmonary artery stenosis, and prominent
forehead and eyes. The diagnosis was later confirmed by
gene sequencing revealing that the patient had a novel G
to A point mutation in exon 20 of JAG1, which changes
a tryptophan to a premature stop codon, a genetic result
that would be consistent with the clinical diagnosis of
Alagille syndrome. In addition, the child had severe fail-
ure to thrive. The child had a repeat liver biopsy
(Figure 2) two months prior to presentation that
revealed, in addition to signs of chronic liver disease
with paucity of bile ducts and bridging fibrosis, several
Figure 3 Chest radiograph consistent with Alagille syndrome
and sarcoidosis. Anterior view chest radiograph revealing extensive
bilateral chronic lung disease, mediastinal adenopathy, butterfly
vertebrae (arrows), and hepatomegaly.
Figure 4 Skin biopsy from the right foot at 28 months. (A)
Granulomatous angiitis with obliteration of the vascular lumina and
slight red cell extravasation in the dermis, and (B) a thrombosed
blood vessel with a granulomatous reaction at the dermal-subcutis
junction. (A and B, hematoxylin and eosin, 132x original
magnification).
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Alagille syndrome).
On physical examination, the child had a temperature
of 103°F, a heart rate of 156 beats per minute, a blood
pressure of 121/53 mm Hg, and had an oxygen require-
ment of 5 L/minute by face mask. He was tachypneic
and grunting. He had shotty lymphadenopathy in his an-
terior and posterior cervical chains as well as in his in-
guinal region. His breath sounds were clear and equal
bilaterally. He had a 3/6 systolic murmur heard best over
the left upper sternal border. He had 2+ femoral and
distal pulses, with <2 second capillary refill distally. The
child’s abdomen was soft and non-tender, with hepato-
megaly, which was baseline for the patient. His spleen
tip was not palpable. On the soles of the child’s feet were
multiple erythematous palpable nodules.
Initial laboratory studies revealed a white blood cell
count of 19.6 thousand cells/μL, with 77% segmented
neutrophils, 7% bands, 14% lymphocytes, and 2% mono-
cytes. His hemoglobin level was 10 g/dL, and his plate-
lets were 635,000/μL. His electrolytes were all within
normal limits, and his total serum protein was elevated
at 8.9 g/dL, with an albumin of 4.2 g/dL.
The child was admitted to the pediatric intensive care
unit for one day because of significant respiratory dis-
tress and started on intravenous broad spectrum
antibiotics. The patient had an echocardiogram that was
normal and revealed no vegetations. He had chest,
abdominal, and pelvic computed tomography and radi-
ography that failed to reveal an abscess or other obvious
infectious process, but did show airspace and interstitial
lung disease more on the right than left, including small
areas with ground glass appearance, mediastinal and
peritracheal adenopathy, butterfly vertebrae, and hepato-
megaly (Figure 3). Abdominal ultrasound showed find-
ings consistent with hepatic granulomata. All blood
cultures were negative, and a bronchoalveolar lavage was
performed that had no hemosiderin-laden macrophages
and was negative for bacteria, fungi, pneumocystis, and
mycobacteria. The patient had a negative tuberculosis
skin test and 3 morning gastric aspirates that did not re-
veal mycobacteria.
Rheumatology was consulted when the infectious evalu-
ation had failed to produce a diagnosis and his C-reactive
protein and erythrocyte sedimentation rate (ESR) were
elevated at 1.69 mg/dL and 80 mm/hr, respectively. An
ophthalmologic examination revealed diffuse creamy
white infiltrates and vascular sheathing consistent with
vasculitis in both eyes. A skin biopsy of a nodule on the
plantar aspect of his foot showed a granulomatous vas-
cular reaction, consistent with granulomatous angiitis
(Figure 4). A serum ACE level was 76 U/L (reference
range: 13–100). The child’s serum lysozyme level was
elevated at 11.9 μg/mL (reference range: 4–10.3). There wasconcern that the child may have been having some joint
pains in his knees at home. Also, during his hospitalization,
he indicated pain in his left elbow and had some mild joint
swelling. Based on the constellation of findings and the
granulomata on the liver biopsy performed 2 months prior,
Rheumatology was concerned for sarcoidosis and recom-
mended that the patient be treated with high dose gluco-
corticoids for 3 days (30 mg/kg/day of intravenous
methylprednisolone). After the first dose, the child’s tachyp-
nea began to improve, his oxygen requirement resolved,
and he became more active. Following the third dose, the
child was started on 2 mg/kg/day of oral prednisolone.
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initiated rather than methotrexate because of concern
of additional liver toxicity in a child with Alagille syn-
drome, and the patient received an infusion of infliximab
of 10 mg/kg. The child’s fevers, joint pains, tachypnea,
oxygen requirement, and rash had resolved 4 days after
starting pulse corticosteroids.
The child was discharged home on prednisolone
(2 mg/kg/day) and mycophenolate mofetil with monthly
infliximab infusions. One month following discharge, his
ophthalmologic examination had returned to normal.
The child initially did well, and a steroid dose wean and
decrease in mycophenolate mofetil to 200 mg once daily
were initiated. Shortly after this change in medication
dosages, the child began having fatigue, joint swelling,
and an elevation in ESR. The child’s infliximab dose was
increased to 20 mg/kg and the dosing interval was shor-
tened to 3 weeks. His prednisolone dose was increased
until his next infliximab infusion. The child continued to
not tolerate steroid weaning, so his infiximab infusion
interval was decreased to 2 weeks and mycophenolate
was returned to twice daily dosing to help decrease the
steroid burden. The child has subsequently tolerated a
steroid wean down to 0.2 mg/kg/day of prednisolone.
His infliximab and methylprednisolone infusions have
been spaced to every 3 weeks, and his arthritis, uveitis,
and pleuritis have been under good control.
Discussion
The coexistence of Alagille syndrome and granulomatous
disease has not been previously described in the literature.
This case report highlights the potential for concurrent
rare conditions in a single pediatric patient. Alternatively,
these conditions may be related in an unrecognized way.
The diagnosis of inflammatory granulomatous disease
in this patient was complicated by several factors. The
patient’s diagnosis of Alagille syndrome could explain
some of his clinical features, such as hepatomegaly and
failure to thrive [7]. In addition, there was a reluctance to
consider two rare diagnoses in one patient [10]. While this
2-year-old child did have rash, arthritis, and eye findings,
his pulmonary involvement, lymphadenopathy, and con-
stitutional symptoms of fever and poor growth represent a
presentation rarely seen in early-onset sarcoidosis [1]. The
skin rash in this child clinically resembled erythema nodo-
sum; however, morphologically, it consisted of granuloma-
tous angiitis (with microthrombi) and primarily involved
the dermis with no evidence of septal panniculitis. This
cutaneous vascular manifestation of sarcoidosis is ex-
tremely rare in adults and not previously reported in chil-
dren [11-14]. Vascular abnormalities, such as vessel wall
abnormalities, aneurysms, vascular stenoses, moya moya,
renovascular hypertension, and intracranial hemorrhage
[15,16] can be seen in Alagille syndrome, though diffusegranulomata consistent with sarcoidosis have not been
described. A young girl with Takayasu arteritis and Alagille
syndrome [15] represents the only known reported case of
Alagille syndrome associated vasculitis.
Sarcoidosis patients may have hypercalcemia secondary
to extrarenal production of calcitriol leading to increased
intestinal absorption of calcium [17]. This child was being
treated for hypocalcemia secondary to gastrointestinal
losses due to his Alagille syndrome. Thus, it is possible
that the child’s Alagille syndrome masked a tendency to-
ward hypercalcemia.
This child’s atypical presentation of sarcoidosis and the
rarity of his two conditions suggest a possible link between
them. Although Alagille syndrome is not typically asso-
ciated with granuloma formation, in one study, there was a
patient with Alagille syndrome who developed a cystic
mandibular mass, which on biopsy revealed multiple cen-
tral giant cell granulomata that were nonmalignant [9].
This case causes speculation that perhaps granulomatous
disease could be a manifestation of Alagille syndrome. Our
patient had granulomata on a liver biopsy during a previ-
ous evaluation 2 months prior to presentation, which at
the time of examination, had been attributed to his Alagille
syndrome. Recent reviews of hepatic granulomas report an
incidence of approximately 4% in unselected liver biop-
sies in adults. The causation of hepatic granuloma can
be determined in most cases and varies by region; non-
infectious immune categories predominate in Western
countries, where infectious causes predominate in the
developing world [18]. Nevertheless, for this child, the
constellation of uveitis, arthritis, pleuritis, and rash in
the setting of an elevated ACE level and granulomas on
biopsy strongly argue in favor of coincident diagnosis
of sarcoidosis.
There may be a molecular basis for our patient’s constel-
lation of findings. The two genes associated with Alagille
syndrome are JAG1 and NOTCH2 [16]. JAG1 encodes a
cell surface ligand for one of the Notch transmembrane
receptors. The role of the Notch signaling proteins is not
well understood, but is highly conserved; JAG1 is on
chromosome 20 and accounts for 70% of the gene muta-
tions in Alagille syndrome [7]. There are four mammalian
Notch receptors (1–4) and five Notch ligands (Jagged1,
Jagged2, Delta-like 1, Delta-like 3, and Delta-like 4) [19].
Of note, JAG1 mutations are not specific for Alagille syn-
drome [16]; in a large kindred study, JAG1 mutations were
associated with congenital right heart obstructive disease
without other diagnostic criteria of Alagille syndrome [20].
It is known that the Notch signaling pathway is im-
portant for regulation of angiogenesis [21]. Notch-1 has
also been recognized as a T cell oncogene and is highly
expressed in the thymus. Specifically, immature lymph-
oid cells that enter the thymus differentiate along the B
cell lineage without Notch signals [19,22]. Notch-1 may
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In one mouse model, thymocytes with a functional γδ T
cell receptor (TCR) were diverted to the αβ lineage with a
constitutive Notch-1 signal [22]. In addition to TCR
lineage, Notch proteins also seem to regulate CD4 TH cell
differentiation; however, there are reports of Notch signal-
ing promoting both TH-1 and TH-2 cell polarization [19].
CD4 T cells incubated with Jagged1-expressing antigen
presenting cells (APC) were induced to a TH-2 cell fate,
and those incubated with APC that over-expressed
Jagged1 were induced to a regulatory T cell fate [19]. Thus,
JAG1 mutations, like those seen in Alagille syndrome, are
likely to alter T cell development within the thymus and
modify effector CD4 T cell differentiation in the peripheral
lymphoid organs. Taken together with the evidence that
over-expression of Jagged1 on APC promotes Treg and
TH-2 CD4 T cell development [19] and intact Notch
signaling is required for appropriate populations of TCRγδ
T cells and TCRαβ T cells [19,22], then it follows that
Jagged1/Notch interactions are critical to immune
homeostasis.
The genetics of sarcoidosis are being investigated.
There are candidate genes located on chromosomes 5 and
6. One such candidate gene is BTNL2 in the major histo-
compatibility complex II region on chromosome 6 [2]. Blau
syndrome has been associated with mutations in CARD15
/NOD2 which results in a gain of function mutation; simi-
lar mutations have been demonstrated in cases of early
onset sarcoidosis [5,6]. The CARD15/NOD2 mutations are
associated with increased basal NF-κB (nuclear factor κB)
activity independent of muramyl dipeptide, a component of
bacterial peptidoglycan, and a ligand for CARD15 in phago-
cytic cells [5]. The NF-κB signaling pathway is preferentially
required for the production of interferon γ (IFNγ) through
a CD4 TH-1 cell mediated pathway [23].
Granulomas are formed by activation of TH-1 cells
and macrophages; thus, sarcoidosis is often considered a
TH-1 mediated disease. Granulomas in early sarcoidosis
express a strong TH-1 phenotype with production of
interleukin-2 and IFNγ, which results in a positive feed-
back loop to recruit additional TH-1 cells and IFNγ pro-
duction [18,24]. Therefore, if CARD15/NOD2 mutations
result in increased basal NF-κB activity, which predis-
pose to a TH-1 cell preference and production of IFNγ,
the resultant phenotypes would have a diffuse granu-
lomatous process [5,18,23,24].
The child described herein has a mutation in JAG1
which results in a truncated protein and is predicted to
result in abnormal or no Jagged1/Notch binding. With-
out this signaling, a predominance of TH-1 phenotype
and uncontrolled TCRγδ T cells would be expected,
which would be similar to the immune phenotype seen
in Blau syndrome with a resultant diffuse granulomatous
process [5].Conclusion
In conclusion, this child has a previously unreported com-
bination of Alagille syndrome and inflammatory multi-
system granulomata consistent with sarcoidosis. In
patients with unusual symptoms, consideration of rare
conditions is warranted even when they have other known
and seemingly unrelated rare conditions. Although this is
the first published report of sarcoidosis and Alagille syn-
drome in the same child, a JAG1 mutation would seem to
predispose a patient to immunologic dysregulation and
the development of granulomas.
Consent
Written informed consent was obtained from the child’s
mother for publication of this case report and any ac-
companying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
Abbreviations
ACE: Angiotensin converting enzyme; CARD15: Caspase recruitment domain
15; NOD2: Nucleotide binding oligomerization domain 2; ESR: Erythrocyte
sedimentation rate; TCR: T cell receptor; APC: Antigen presenting cell;
NF-κB: Nuclear factor κB; IFNγ: Interferon γ.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MM and MZ drafted the manuscript. TB and RQC were involved in the
patient care, participated in the manuscript's design and coordination, and
critically revised the manuscript. DK provided figures and assistance with
histological data and assisted with manuscript revision. All authors have
reviewed the final manuscript and gave approval for publication.
Acknowledgement
RQC is supported by the Arthritis Foundation, Alabama Chapter Endowed Chair
in Pediatric Rheumatology. Divisional research is also supported by Dr. Joe B.
and Cornelia B. LaRussa.
Author details
1Department of Pediatrics, Division of Rheumatology, University of Alabama
at Birmingham, Birmingham, AL, USA. 2Department of Pediatrics, Division of
Neonatology, University of Alabama at Birmingham, Birmingham, AL, USA.
3Department of Pathology, University of Alabama at Birmingham,
Birmingham, AL, USA.
Received: 22 June 2012 Accepted: 20 August 2012
Published: 31 August 2012
References
1. Cimaz R, Ansell BM: Sarcoidosis in the pediatric age. Clin Exp Rheumatol
2002, 20:231–237.
2. Shetty AK, Gedalia A: Childhood sarcoidosis: A rare but fascinating
disorder. Pediatr Rheumatol Online J 2008, 6:16.
3. Tomita H, Sato S, Matsuda R, Sugiura Y, Kawaguchi H, Niimi T, et al: Serum
lysozyme levels and clinical features of sarcoidosis. Lung 1999,
177:161–167.
4. Cron RQ, Wallace CA, Sherry DD: Childhood sarcoidosis–does age of onset
predict clinical manifestations? J Rheumatol 1997, 24:1654–1656.
5. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S,
et al: Early-onset sarcoidosis and CARD15 mutations with constitutive
nuclear factor-kappaB activation: common genetic etiology with Blau
syndrome. Blood 2005, 105:1195–1197.
Mannion et al. Pediatric Rheumatology 2012, 10:32 Page 6 of 6
http://www.ped-rheum.com/content/10/1/326. Rosé CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, Davey
MP, et al: Blau syndrome mutation of CARD15/NOD2 in sporadic early
onset granulomatous arthritis. J Rheumatol 2005, 32:373–375.
7. Krantz ID, Piccoli DA, Spinner NB: Clinical and molecular genetics of
Alagille syndrome. Curr Opin Pediatr 1999, 11:558–564.
8. Mueller RF: The Alagille syndrome (arteriohepatic dysplasia). J Med Genet
1987, 24:621–626.
9. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA:
Features of Alagille syndrome in 92 patients: frequency and relation to
prognosis. Hepatology 1999, 29:822–829.
10. Wardrop D: Ockham's razor: sharpen or re-sheathe? J R Soc Med 2008,
101:50–51.
11. Takemura T, Shishiba T, Akiyama O, Oritsu M, Matsui Y, Eishi Y: Vascular
involvement in cutaneous sarcoidosis. Pathol Int 1997, 47:84–89.
12. Wei CH, Huang YH, Shih YC, Tseng FW, Yang CH: Sarcoidosis with
cutaneous granulomatous vasculitis. Australas J Dermatol 2010,
51:198–201.
13. Petri M, Barr E, Cho K, Farmer E: Overlap of granulomatous vasculitis and
sarcoidosis: presentation with uveitis, eosinophilia, leg ulcers, sinusitis,
and past foot drop. J Rheumatol 1988, 15:1171–1173.
14. García-Porrúa C, González-Gay MA, García-País MJ, Blanco R: Cutaneous
vasculitis: an unusual presentation of sarcoidosis in adulthood. Scand
J Rheumatol 1998, 27:80–82.
15. Kavukçu S, Demir K, Soylu A, Anal O, Saatçi O, Göktay Y: A case of Takayasu
disease with findings of incomplete Alagille syndrome. Rheumatol Int
2005, 25:555–557.
16. Online Mendelian Inheritance in Man, OMIMW. Baltimore, MD: Johns Hopkins
University; MIM Number: {118450- ALAGILLE SYNDROME 1; ALGS1}: {02/21/
2012}. World Wide Web URL: http://omim.org/.
17. Sharma OP: Vitamin D, calcium, and sarcoidosis. Chest 1996, 109:535–539.
18. Lagana SM, Moreira RK, Lefkowitch JH: Hepatic granulomas: pathogenesis
and differential diagnosis. Clin Liver Dis 2010, 14:605–617.
19. Osborne BA, Minter LM: Notch signalling during peripheral T-cell
activation and differentiation. Nat Rev Immunol 2007, 7:64–75.
20. Eldadah ZA, Hamosh A, Biery NJ, Montgomery RA, Duke M, Elkins R, et al:
Familial Tetralogy of Fallot caused by mutation in the jagged1 gene.
Hum Mol Genet 2001, 10:163–169.
21. Gridley T: Notch signaling in vascular development and physiology.
Development 2007, 134:2709–2718.
22. Deftos ML, Bevan MJ: Notch signaling in T cell development. Curr Opin
Immunol 2000, 12:166–172.
23. Aronica MA, Mora AL, Mitchell DB, Finn PW, Johnson JE, Sheller JR, et al:
Preferential role for NF-kappa B/Rel signaling in the type 1 but not type
2T cell-dependent immune response in vivo. J Immunol 1999,
163:5116–5124.
24. Gerke AK, Hunninghake G: The immunology of sarcoidosis. Clin Chest Med
2008, 29:379–390. vii.
doi:10.1186/1546-0096-10-32
Cite this article as: Mannion et al.: Sarcoidosis in a young child with
Alagille syndrome: a case report. Pediatric Rheumatology 2012 10:32.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
